

Said Soubra, MD, MBA, FCCP

CEO, Owner and Founder
Pulmonary Specialty Group
Cell: (512) 633-2434
Soubra@psgclinics.com

Undergraduate Education

- Bachelor's degree in Chemistry 9/1989- 6/1992
- American University of Beirut - Beirut, Lebanon

Medical Education

- MD
- American University of Beirut - Beirut, Lebanon 9/1992- 6/1996

Postgraduate Training

Rotating internship American University of Beirut 7/1996-6/1997

Internal Medicine Residency 7/1997- 6/2000

- University of Kansas-School of Medicine - Wichita, Kansas
- Chief Residency Internal Medicine

Pulmonary and Critical Care Fellowship 7/2000- 6/2003

- Baylor College of Medicine - Houston, TX

Pulmonary Transplant Fellowship 7/2001- 6/2002

- Baylor College of Medicine - Houston, TX
- The Methodist Hospital
- St Luke's Episcopal Hospital

Sleep Medicine Training 12/2002- 6/2003

- Baylor College of Medicine - Houston, TX
- The Veterans Affairs Hospital Sleep Lab

MBA Healthcare 12/2020

- Western Governor University

Specialized Training and Expertise

- Interventional Pulmonary: Medical pleuroscopy, Indiana University, Indiana Sep 2004
- Agent Orange medical examinations for benefit determinations 1/03-12/08
- 12th Annual Assembly of the American Association of Bronchology Oct 2004
- Percutaneous tracheostomy, Bronchoscopic Ultrasound hands on training Nov 2005
- Ascension Executive Clinical Leadership Program 2/16-2/17
- ION navigational bronchoscopy 03/2023
- Asbestos A-reader and independent medical examinations 06/2015-
- Pulmonary Independent medical evaluation expert- Burn Pit exposure 04/2024-

Academic Appointments

Current faculty Appointments

- Clinical Assistant Professor - Texas A&M Medical School 6/2012-present
 - Director, Critical Care medicine - Round Rock Campus
- Clinical Professor - Texas State University – Round Rock Campus 9/2018-present
 - Department of Respiratory Care & Texas State Sleep Center
 - Director of the sleep laboratory

Previous Faculty Position

- Assistant Professor of Medicine - Baylor College of Medicine 12/2003- 12/2007
 - Section of Pulmonary and Critical Care

Administrative Appointments

- CEO, owner and founder of Pulmonary Speciality Group 04/2024-present
- Vice President, USACS 7/2018-present
- National Director of Critical Care, USACS 10/2018-present
- Chief Medical Officer - Seton Medical Center Williamson 8/2015-12/31/2017
- Vice President, Austin Critical Care Specialists 4/2014-07/2018
- Chief of Staff, Seton Medical Center Williamson 1/2014-8/2015
- Chief of Staff, Cornerstone Hospital Round Rock 12/2013-8/2015
- Vice Chief of staff, Seton Medical Center Williamson 1/2012-1/2014
- Secretary of the Medical Staff, Seton Medical Center Williamson 1/2010-1/2012
- Medical Director, Intensive Care Unit - Seton Medical Center Williamson 1/2008-present
- Medical Director, Williamson Pulmonary and Sleep Associates - Sleep Center 1/2010-1/2015
- Medical Director, Alpha Sleep Labs 1/2012-10/2023
- Medical Director, Frontera - In-office diagnostic testing 2/2012-7/2015
- Medical Director, SNW and SMCW Sleep Centers 1/2009-1/2012
- Medical Director, Pulmonary Program - Reliant Rehab 1/2012-1/2014
- Director, Medical Intensive Care Unit Michael E. Debakey VAMC 6/2004-12/2007
- Chief of Respiratory & Intensive Care Services Michael E. Debakey VAMC 6/2005-12/2005
- CPR Committee Chair Michael E. Debakey VAMC 6/2005-12/2007
- Interim Medical Director of the ACLS course Michael E. Debakey VAMC 6/2005- 12/2007
- Critical Care Committee Co-Chair Michael E. Debakey VAMC 12/2005- 12/2007
- Baylor College of Medicine ACLS committee-member 12-2005- 12/2007

Honors and Awards:

- Dean's Honor List, Medical School 1995
- American College of Physician Kansas Chapter, Abstract Presentation 1st Prize winner 1999
- American College of Physician Kansas Chapter, Abstract Presentation 2nd Prize Winner 1999
- Chief Residency, Internal Medicine, University of Kansas School of Medicine- Wichita 1999-2000
- 6th Leadership Development for Academic Physicians Program Award (ACCP 2004)
- VISN-16 ICU utilization workgroup recognition award. March 2005
- Fellow of the American College of Physicians 2004

Certification:

- American Board of Internal Medicine/ Critical Care Medicine Board Certified 2003, 2013
- American Board of Sleep Medicine Board Certified 2004
- American Board of Internal Medicine/ Pulmonary Disease Board Certified 2002, 2012, 2022
- American Board of Internal Medicine/ Internal Medicine; Board Certified 2000
- ECFMG Certificate
- USMLE Step 3 05/1998
- USMLE Step 2 03/1996
- USMLE Step 1 06/1995
- Basic Life support
- ATLS certified 2003-2007
- Texas Medical License L7568
- Ohio Medical License 35.145410
- Fellow of the American College of Physicians
- ACLS provider 2005-current
- ACLS instructor 2006
- ENLS certified 2022

Medical Association Membership

- Current:
 - American College of Chest Physicians (FCCP)
 - American Thoracic Society
 - Society of Critical Care Medicine
- Past:
 - American College of Physicians 1997-2000
 - American Society of Transplantation 2002
 - American Academy of Sleep Medicine 2004-2005

Editorial - Ad-Hoc Reviewer

- Journal of Chest since 2004- 2008
- American Journal of Respiratory and Critical Care Medicine March 2005- 2008
- Critical Care medicine 2005- 2008
- Respiratory Medicine 2006-2008
- Invited reviewer for the Cleveland Clinic Journal of Medicine Aug 2005
- Abstract Reviewer: ACCP congress 2006
- American Board of Internal Medicine Board exam reviewer 2005-2006

Research Support

- **Prior Research Support - Inactive:**
 - 1) AN-1996 "MECHANISMS OF MICROVASCULAR THROMBOSIS IN ENDOTOXEMIA"
NIH/NHLBI HL-64721 (7/1/01-5/31/06), HL-070357 (9/29/03-8/31/08), HL-079368 (4/1/06-3/31/11)
Co-investigator
PI: Rolando Rumbaut
 - 2) H-18283 "COMPASSIONATE USE OF THE EMPHASYS ENDOBRONCHIAL VALVE IN THE TREATMENT OF UNILATERAL NATIVE LUNG HYPERINFLATION IN A LUNG TRANSPLANT RECIPIENT"
BCM internal funding
PI
 - 3) H-12006 "NEUTROPHILS, NITRIC OXIDE AND MICROVASCULAR PERMEABILITY"
BCM internal Funding
Co-PI
 - 4) H-15009 "TREATMENT OF HYPERGLYCEMIA IN ISCHEMIC STROKE (THIS) TRIAL"
NIH
Co-investigator
 - 5) H-15295 "AMB-320, ARIES-1 - AMBRISENTAN IN PAH - A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY STUDY OF AMBRISENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
Myogen
Co-investigator
 - 6) H-15310 "AMB-320/321-E - A LONG-TERM STUDY OF AMBRISENTAN IN PULMONARY ARTERIAL HYPERTENSION SUBJECTS HAVING COMPLETED AMB-320 OR AMB-321"
Myogen
Co-investigator
 - 7) H-16585 "A PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY OF CEFTOBIPROLE MEDOCARIL VERSUS LINEZOLID PLUS CEFTAZIDIME IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA, PROTOCOL NO.: BAP00248, CHOPIN-1"
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
Co-investigator

- 8) H-17375 "ACTIVE C200-003: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE SAFETY AND PILOT EFFICACY OF ILOPROST INHALATION SOLUTION IN ADULTS WITH ABNORMAL PULMONARY ARTERIAL PRESSURE AND EXERCISE LIMITATION ASSOCIATED WITH MILD-TO-MODERATE IDIOPATHIC PULMONARY FIBROSIS"
CoTherix, Inc
Co-investigator H-17437 "AMB 220 E - AN OPEN-LABEL, LONG-TERM STUDY OF AMBRISENTAN IN PULMONARY HYPERTENSION SUBJECTS HAVING COMPLETED MYOGEN STUDY AMB-220 - FORMERLY H-13619"
Myogen
Co-investigator
- 9) H-17539 "A RANDOMIZED, MULTIPLE-DOSE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL GROUP EFFICACY AND SAFETY STUDY TO DETERMINE THE OPTIMUM DOSE OF BEA 2180 BR DELIVERED BY THE RESPIMAT INHALER IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BIPI PROTOCOL NO. 1205.4"
Boehringer Ingelheim Pharmaceuticals
Co-investigator
- 10) H-17742 "A RANDOMIZED, MULTIPLE-DOSE, DOUBLE-BLIND, CROSSOVER STUDY TO COMPARE THE EFFICACY AND SAFETY OF 200 UG AND 400 UG OF BEA 2180 BR TO TIOTROPIUM 5 UG AND PLACEBO WHEN EACH IS DELIVERED BY THE RESPIMAT INHALER IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BIPI PROTOCOL NO. 1205.6"
Boehringer Ingelheim Pharmaceuticals, Inc
Co-investigator
- 11) H-18029 "VIRAL-INDUCED T CELL RESPONSES IN COPD EXACERBATION PROTOCOL: LES COPD"
NIH
Co-investigator
- 12) H12852 "Efficacy of empiric positive airway pressure in patients awaiting diagnostic PSG"
BCM internal funding
Co-investigator 11/8/2002 –
- 13) H14598 "Venticute (RSP-C Surfactant) in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment (VALID study) A randomized, multinational, multicenter, parallel group, double blind control group study"
Altana Pharma AG, Protocol Number: BY2001/M1-007
Co-investigator 10/16/2003 –
- 14) H14881 "Endobronchial valve for emphysema palliation trial (VENT)"
Emphasys Medical, Inc, Protocol Number: 630-0001-H
Co-investigator 11/20/2003 – 1/26/2006
- 15) H13102 "A Multicenter, Multinational, Long-term Extension Study, To Assess The Safety And Toleration Of Subject Optimized Treatment Regimens Of Oral Sildenafil For Pulmonary Arterial Hypertension In Subjects Who Have Completed Study A1481140"
Pfizer, Protocol Number: A1481140/06/08/2002
Co-investigator 12/16/2002- 10/20/2005
- 16) H13813 "A Multinational, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study To Assess The Safety And Efficacy of A Subject Optimised Dose Of Sildenafil (20, 40, OR 80 MG Sildenafil TID) Based On Toleration, When Used In Combination With Intravenous Prostacyclin (Epoprostenol) In The Treatment of Pulmonary Arterial Hypertension"
Pfizer Global Research and Development, Protocol Number: A1481141
Co-investigator 5/21/2003 – 4/7/2005
- 17) H13886 "A Multicenter, Multinational, Long-term, Open-Label Extension Study, To Assess The Safety Of Subject Optimized Treatment Regimens Of Oral Sildenafil When Used In Combination With Intravenous

Prostacyclin (Epoprostenol) For Pulmonary Arterial Hypertension in Subjects Who Have Completed Study A1481141”

Pfizer Global Research and Development, Protocol Number: A1481153

Co-investigator 5/21/2003- 4/21/2005

- 18) H13914 “AC-052-320 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Assess The Efficacy, Safety And Tolerability Of Bosentan In Patients with Idiopathic Pulmonary Fibrosis”
Actelion, Protocol Number: AC-052-320
Co-investigator 6/24/2003- 8/11/2005
- 19) H13928 “A Phase III, Randomized, Double-blind, Placebo-Controlled Safety And Efficacy Study Of Sitaxentan Sodium Treatment With An Open-Label Bosentan (Tracleer) Arm In Patients With Pulmonary Arterial Hypertension”
Encysive, L.P, Protocol Number FPHO2
Co-investigator 6/24/2005-8/4/2005
- 20) H-13930 “ Open label study to evaluate the long term safety of Sitaxsentan sodium treatment with a Bosentan arm in patients with pulmonary arterial hypertension”
Encysive, L.P., Protocol Number: FPH02-X
Co-investigator 6/24/2003- 10/19/2005
- 21) H-14089 “ Open-Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension”
Encysive, L. P., Protocol Number. FPH03
Co-investigator 6/30/2003 – 10/19/2005
- 22) H- 14182 “ An open-label Study Of The Safety Of Subcutaneous Recombinant Interferon Gamma-1-B In Patients With Idiopathic Pulmonary Fibrosis”
INTERMUNE , INC, Protocol Number: GIPF-006
Co-investigator 7/23/2003 – 9/7/2005
- 23) H14325 “ The effect of Endothelin A& B Receptor Antagonist (ETRA) On Aldosterone Levels In Patients With Pulmonary Arterial Hypertension”
BCM Internal Funding
Co-investigator 8/14/2003- 10/5/2005
- 24) H- 14493 “A randomized, double blind, placebo-controlled trial of prophylactic heparin in patients with severe sepsis and higher disease severity who are undergoing treatment with Drotrecogin Alfa (activated)”
Eli Lilly and Company, Protocol Number F1K-MC-EVBR
Co-investigator 9/22/2003 – 9/29/2005
- 25) H-15043 “GIPF-007: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of The Safety And Efficacy Of Interferon Gamma-1-B In Patients With Idiopathic Pulmonary Fibrosis”
INTERMUNE , INC, Protocol Number: GIPF-007
Co-investigator 2/13/2004 – 2/2/2006
- 26) H-15483 “ Comparison of Tacrolimus/Sirolimus/Prednisone Regimen Vs Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung transplantation”
FUJISAWA HEALTHCARE INC
Co-investigator 6/3/2004- 6/23/2005
- 27) H- 15505 “Multiple Modality Antibody Reduction In Highly Sensitized Lung Transplant Candidates”
BCM Internal Funding
Co-investigator 11/15/2004- 12/7/2005
- 28) H15653 “ A placebo-controlled study to evaluate the safety and pilot efficacy of Iloprost inhalation solution as add-on therapy with Bosentan in subjects with pulmonary arterial hypertension”
CoTherix, Protocol Number: C200-002
Co-investigator 4/26/2004- 5/26/2005

- 29) H-15763 “ Early: Endothelin Antagonist Trial In Mildly Symptomatic PAH Patients A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess The Efficacy, Safety And Tolerability Of Bosentan In Patients With Mildly Symptomatic Pulmonary Arterial Hypertension”
Actelion Pharmaceuticals Ltd. Protocol Number: AC-052-364
Co-investigator 6/4/2004- 7/7/2005
- 30) H-16069 “ A Facilitated Access Program To Provide Everolimus (RAD) For Maintenance For Patients Completing Therapy In RAD Trials In Solid Organ Transplantation”
Novartis, Protocol Number: CRAD001 A 2401
Co-investigator 7/15/2004- 7/28/2005
- 31) H-8841 “A randomized, double-blind, placebo-controlled Phase III study of the safety and efficacy of subcutaneous recombinant interferon Y1b (IFN-Y1B) in patients with idiopathic pulmonary fibrosis”
INTERMUNE, INC, Protocol Number: GIPF-001
Co-investigator
- 32) H-12398 “ Efficacy and Safety of Drotrecogin Alfa (activated) in Adult patients with early stage severe sepsis”
Eli Lilly and Company, Protocol Number: F1K-MC-EVCL
Co-investigator
- 33) H 12437 “ A phase II, Randomized, double-blind, dose- controlled, dose-ranging, multicenter study of BSF 208075 evaluating exercise capacity in patients with moderate to severe pulmonary arterial hypertension”
Myogen, Inc
Co-investigator
- 34) H 12574 “A Multinational,Multicentre, Randomized, Double-blind, Double-Dummy, Placebo-Controlled Study To Assess The Efficacy And Safety Of 20, 40, And 80 mg TID of Sildenafil In the Treatment Of Pulmonary Arterial Hypertension In Subjects Aged 18 Years and Over”
Pfizer, Protocol Number: A1481140
Co-investigator
- 35) H 12608 “A Multicenter, Randomized, Parallel Placebo-Controlled Study Of the Safety And Efficacy of Subcutaneous Remodulin Therapy After transition From Fololan In Patients with Pulmonary Arterial Hypertension”
United Therapeutics, Protocol Number: P01:13
Co-investigator
- 36) H 12671 “An Open-Label Study Of the Safety And Efficacy Of Subcutaneous Recombinant Interferon Gamma- 1B (IFN-Y 1B) In Patients With Idiopathic Pulmonary Fibrosis”
INTERMUNE, INC, Protocol Number: GIPF-004
Co-investigator
- 37) H 12838 “A Multicenter, Open-Label, Single-Arm Safety Study To Investigate The Effects Of Chronic Tracleer Treatment On Testicular Function In Male Patients With Pulmonary Arterial Hypertension”
Actelion, Protocol Number: AC-052-402
Co-investigator
- 38) H-13049 “A Phase III, Randomized, Double-Blind Placebo-Controlled, PSG Plus Outpatient Study To Determine The Safety And Efficacy Of TAK-375 In Adults With Chronic Insomnia”
Takeda Pharmaceuticals North America, Protocol Number: 01-02-TL-375-021
Co-investigator
- 39) H-13914 “A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Assess The Efficacy, Safety And Tolerability Of Bosentan In Patients with Idiopathic Pulmonary Fibrosis”
Actelion, Protocol Number: AC-052-320
Co-investigator

- 40) H-13928 “A Phase III, Randomized, Double-blind, Placebo-Controlled Safety And Efficacy Study Of Sitaxentan Sodium Treatment With An Open-Label Bosentan (Tracleer) Arm In Patients With Pulmonary Arterial Hypertension”
Encysive, L.P., Protocol Number: FPH02
Co-investigator
- 41) H-13930 “Open label study to evaluate the long term safety of Sitaxsentan sodium treatment with a Bosentan arm in patients with pulmonary arterial hypertension”
Encysive, L.P., Protocol Number: FPH02-X
Co-investigator
- 42) H-14089 “Open-Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension”
Encysive, L.P., Protocol Number: FPH03
Co-investigator
- 43) H-14182 “An Open-label Study Of The Safety Of Subcutaneous Recombinant Interferon Gamma-1B (IFN-Gamma 1B) In Patients With Idiopathic Pulmonary Fibrosis”
INTERMUNE , INC, Protocol Number: GIPF-006
Co-investigator
- 44) H-14325 “The effect of endothelin A&B receptor A&B receptor antagonist (ETRA) on aldosterone levels in patients with pulmonary arterial hypertension”
BCM Internal Funding
Co-investigator
- 45) H15295 “Aries-1- Ambrisentan in PAH- a phase III, randomized, double blind, placebo-controlled, multicenter, efficacy study of ambrisentan in subjects with pulmonary arterial hypertension”
Myogen
Co-investigator
- 46) H-15310 “AMB-320/321-E - A Long-term Study Of Ambrisentan In Pulmonary Hypertension Subjects Having Completed AMB-320 or AMB-321”
Myogen
Co-investigator

Publications

- **Published Papers**
 - Ari A, Blain K, Soubra S, Hannia NA, Treating COPD patients with inhaled medications in the Era of COVID-19 and Beyond:Options and Rationale for Patients at Home, Int J Chron Obstruct Pulmon Dis 2021;Sep 28; 16: 2687-95
 - VENT study group, Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy; Eur Respir J. 2014 Feb;43(2):387-96
 - Collins KP, Babar H, Soubra SH, Dyspnea associated with dermatomyositis, Respir Care, 2011 Dec;56(12):1962-5
 - VENT study group; A randomized study of endobronchial valves for advanced emphysema; N Engl J Med. 2010 Sep 23;363 (13): 1233-44
 - Patel KN, Soubra SH, Lam FW, Rodriguez MA, Rumbaut RE; Polymicrobial sepsis and endotoxemia promote microvascular thrombosis via distinct mechanisms, J Thromb Haemost 2010, Jun; 8(6):1403-9
 - Patel KN, Soubra SH, Bellera RV, Dong JF, McMullen CA, Burns AR, Rumbaut RE, Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia, Arterioscler Thromb Vasc Biol.2008 Dec;28(12):2225-30
 - Burns AR, Zheng Z, Soubra SH, Chen J, Rumbaut RE, Transendothelial flow inhibits neutrophil transmigration through a nitric oxide-dependent mechanism: potential role for cleft shear stress; Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2904-10

- Soubra SH, Guntupalli KK. Critical illness in pregnancy an overview. Critical Care Medicine 2005; 33: S248-55
- Soubra SH, Guntupalli KK: Acute Respiratory Failure in Asthma, Indian Journal of Critical Care Medicine 2006; 9(4): 225-234
- Chandra D, Soubra SH, Musher D, A 57 year old male with a fluid-containing lung cavity: infection of an emphysematous bulla with MRSA, Chest 2006; 130(6): 1942-6
- **Abstracts**
 - POLYMICROBIAL SEPSIS AND ENDOTOXIN ENHANCE MICROVASCULAR THROMBOSIS SIMILARLY BY A P-SELECTIN INDEPENDENT MECHANISM.
Said H. Soubra, Emily M. Eagen, Ricardo V. Bellera, Alan R. Burns, Rolando E. Rumbaut (Federation of American Societies for Experimental Biology FASEB meeting May 2007)
 - THE INCIDENCE, IMPACT, AND MANAGEMENT OF HUMORAL REJECTION IN LUNG TRANSPLANTATION. Tarik Haddad, MD¹, Ramesh Kesavan, MD¹, Gnananandh Jayaraman, MD¹, Yavuz Silay, MD¹, George Noon, MD¹, Matthias Loebe, MD¹, Osama Gaber, MD², Nadine Haykal², Said Soubra, MD¹, Charlie Lan, DO¹, Phillip Cagle, MD², Anna Sienko, MD², Roberto Barrios, MD² and Harish Seethamraju, MD¹ (American Transplant Congress May 2007)
 - Mankidy B, Seethamraju H, Silay Y, Soubra S, Lan C, Noon G, Loebe M, LaFuente J, Scheinin S, Land G, Bracey A, Bag R, Multiple Modality Antibody Reduction In Highly Sensitized Lung transplant Candidates (presented at the ACCP Congress meeting 2006, Top 10 best Posters award finalist)
 - Burns, Alan; Zheng, Zhilan; Soubra, Said; Chen, Jie; Rumbaut, Rolando, Transendothelial pressure inhibits neutrophil transmigration via a nitric oxide-dependent mechanism: a potential role for cleft shear stress (Presented at the Society of Leukocyte biology meeting San Antonio Tx , November 2006)
 - S. Soubra*, E. Eagen*, R. Bellera*, R. Rumbaut , SIMILAR EFFECTS OF ENDOTOXEMIA AND CECAL LIGATION/PERFORATION ON MICROVASCULAR THROMBOSIS IN VENULES AND ARTERIOLES IN VIVO. (Shock society meeting June 2006, Broomfield CO)
 - S.H.Soubra, D. Venarske, R. Bag, A.E. Frost; C2 Cyclosporine Levels Correlates Best with Area Under the Curve in Pancreatic Insufficient Cystic Fibrosis Patients (Abstract presented at International Society of Heart Lung Transplantation meeting 2002 Washington DC)
 - S.H.Soubra, D. Vernaske, R. Bag, A. E. Frost; C4 Levels of Tacrolimus Correlates Best with Area Under the Curve In Pancreatic Insufficient Cystic Fibrosis Patients. (Abstract presented at International Society of Heart Lung Transplantation meeting 2002 Washington DC)
 - R. Raj, S. Soubra, R. Bag, A. Frost; Lung retransplantation for Posttransplant Lymphoproliferative Disorder: Clinical Experience of a single center (Abstract presented at American Thoracic Society 2002)
 - C. Reimer , S. Soubra , R. Dickson, ; Physician Response To Medicare Reimbursement For Screening Tests (Abstract presented at American College of Physicians Kansas Chapter 2000-winner of 1st prize 300\$)
 - C. Reimer , S. Soubra , R. Dickson, ; Physician Response To Medicare Reimbursement For Screening Tests (Abstract Presented at the American College of Physicians, National Meeting Philadelphia 2000)
 - S. Soubra, Richard Claiborne; Hazardous Hot Tubs Mycobacterium (abstract presented at ACP Kansas Chapter 2000- winner of second prize 200\$)
 - S.Soubra et al. ; Effect of the Zouk Power Plant on respiratory diseases and general health of the surrounding community, an epidemiologic study (presented at the Medical epidemiology seminar A.U.B. July 1993)

Prior Teaching Information (12/2003-12/2007):

- **Non- didactic teaching**
 - Director of the Medical ICU course for the Baylor College of Medicine medical students at the MEDVAMC
 - Co-Director of the Medicine Sub-internship at the MEDVAMC.
 - Non-didactic teaching expected at BCM: Teaching and training of students, residents and fellows on service at the VA hospital, the Methodist hospital and St Luke's hospital pulmonary transplant service
 - Preceptor for the 3rd year medical student PPS-3 course, Baylor College of Medicine 2005
 - Resident Training: Supervision and training of resident during Internal Medicine Residency, Chief residency and Pulmonary Critical Care Fellowship, and as faculty at Baylor college of medicine
 - Clinical Fellow Training: Participated in supervision and training of 1st year pulmonary / critical care fellows during my pulmonary transplant fellowship
 - Teaching of medical students, residents and pulmonary and critical care fellows on pulmonary consult service, lung transplant service, and medical intensive care unit.
 - Resident training:

- 6 residents per month- 30 hrs/weeks while attending
 - Pulmonary Critical Care Fellow training:
 - 1-2 fellows per month- 30 hrs/week while attending
- **Didactic teaching**
 - **Curriculum**
 - Development of a core curriculum lecture series for the pulmonary and critical care fellowship
 - Development of a core curriculum lecture series for the lung transplant fellowship
 - Development of the ICU Mortality and Morbidity Conference
 - **Lectures**
 - Lung transplantation, Recipient Selection; BCM pulmonary and critical care fellow core curriculum 11/2003
 - Interstitial Lung Diseases, BCM Physician assistant pulmonary core curriculum 12/200
 - Pulmonary symptoms and signs, BCM Physician assistant pulmonary core curriculum 12/2001
 - Pulmonary manifestation of autoimmune diseases, Internal Medicine Grand Round, University of Kansas-school of Medicine-Wichita 1/2000
 - Ventilator Associated Pneumonia, ICU nurses symposium on VAP, Michael E. Debakey VAMC, Houston, Sep 2004
 - Mechanical Ventilator weaning, 15th annual respiratory care seminar, Michael E Debakey VAMC, Houston, oct 2004
 - Interstitial Lung diseases, Internal Medicine Residency Core Curriculum, Baylor College of Medicine, Houston, Tx Nov 2004, Nov 2005
 - Altered Mental Status, Medical student monthly curriculum lecture series, MEDVAMC Nov 2004 and monthly
 - Bronchoscopic Lung Volume Reduction, VA Grand Rounds, Michael E. Debakey VAMC, Dec 2004
 - Pulmonary review in Family Medicine, Family Medicine Board Review Course, Marriot Houston , May 2005
 - Central venous catheterization, VA internal medicine residents curriculum, MEDVAMC, March 2005, July 2005
 - Nosocomial Pneumonia, Pulmonary and Critical Care fellows core curriculum, Baylor College of Medicine, April 2004, Nov 2004, Nov 2005
 - The Chest X ray, Medical study core curriculum lectures MEDVAMC, July 2005, Sep 2005, Jan 2006
 - Air space disease, Chest x ray conference, pulmonary critical care department, Baylor College of Medicine, September 2005
 - COPD a major Health problem, 17th Annual Texas Nurse Practitioners Conference, Houston, TX, September 2005
 - Acute MI, MEDVAMC ACLS course, MEDVAMC Houston TX, 11/2005
 - Developmental abnormalities of the pulmonary vasculature, Chest x ray conference, Pulmonary critical care department, Baylor College of Medicine, Feb 2006
 - Sepsis, Morbidity and Mortality Conference, MEDVAMC M&M, MEDVAMC Houston TX, 3/2006
 - Sepsis Lecture 1, Pulmonary and Critical Care Medicine Core curriculum lectures, April 20006, BCM , Houston TX Sepsis Lecture 1, Pulmonary and Critical Care Medicine Core curriculum lectures, April 20006, BCM , Houston TX
 - Sepsis Lecture 2, Pulmonary and Critical Care Medicine Core curriculum lectures, May 20006, BCM , Houston TX